ArticleJournal of endocrinological investigation2026
Predictive value of serum CCL18 for recurrence and invasiveness in pituitary neuroendocrine tumors.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to investigate the predictive value of serum CCL18 in the recurrence and invasiveness of pituitary neuroendocrine tumors (PitNETs). CCL18, a chemokine secreted mainly by tumor-associated macrophages, has been implicated in cancer progression, but its role in PitNETs remains unexplored.
methodA total of 463 patients with PitNETs (110 recurrent and 353 non-recurrent) who underwent surgery at Beijing Tiantan Hospital between 2020 and 2022, along with 32 healthy controls, were retrospectively analyzed. Serum CCL18 concentrations were measured by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Cat# DCC180). Clinical, radiological, and pathological parameters were assessed, and subgroup analyses were performed according to recurrence and invasiveness. Statistical analyses were conducted using SPSS 26.0, and receiver operating characteristic (ROC) curves were generated with GraphPad Prism 8.0. In addition, CCL18 mRNA expression in recurrence PitNETs and non-recurrence PitNETs tissues was validated by quantitative real-time PCR (qPCR).
resultsSerum CCL18 was higher in recurrent than non-recurrent PitNETs (median: 46253 vs. 27834 pg/mL, P < 0.001) and elevated in invasive tumors. ROC analysis showed an AUC of 0.801 (95% CI: 0.752–0.850), with 84.9% sensitivity and 79.2% specificity for recurrence. CCL18 correlated with Knosp grade and Ki-67 index (P < 0.001) and remained an independent predictor in multivariate analysis. qRT-PCR revealed CCL18 mRNA was upregulated in recurrence PitNET tissues versus non-recurrence PitNETs tissues (P < 0.001), suggesting systemic elevation may reflect tumor microenvironment secretion. Recurrent invasive PitNETs had the highest CCL18 levels.
conclusionsSerum CCL18 is associated with PitNETs recurrence and invasiveness and may serve as a non-invasive biomarker. Combined tissue and serum assessment could improve risk stratification and prognostic evaluation.
Indexed as
Identifiers
41591730What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.